Investigating the Efficacy Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

  • STATUS
    Recruiting
  • End date
    Jul 31, 2024
  • participants needed
    60
  • sponsor
    FibroGen
Updated on 24 July 2021

Summary

This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD of roxadustat in ESA-nave and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as well as end-stage renal disease (ESRD) who are receiving either hemodialysis (HD) or peritoneal dialysis (PD). The study will enroll patients between the ages of 2 to <18 years in two sequential cohorts, with the older cohort of ages 12 to <18 years enrolled first. Approximately 30 patients will be enrolled in each age-based cohort.

Details
Condition Anemia Associated With Chronic Kidney Disease
Treatment Roxadustat
Clinical Study IdentifierNCT04621331
SponsorFibroGen
Last Modified on24 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Clinically stable CKD in the opinion of the investigator
Estimated glomerular filtration rate (Bedside Schwartz formula) of < 60 ml/min/1.73 m2 (stage 3, 4 and 5 CKD) for non-dialysis patients, or patients who are receiving chronic dialysis (hemodialysis or peritoneal dialysis) for ESRD
For ESA-nave patients (either NDD or DD; ESA-nave is defined as those patients whose total duration of prior ESA exposure is 3 weeks within the preceding 12 weeks at the time informed consent is obtained), mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be < 11.0 g/dL. For patients currently receiving stable ESA dosing who will discontinue ESA and convert to roxadustat during study, mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be 10.0 g/dL and 12.5 g/dL
Ferritin >50 ng/mL and transferrin saturation >10% (obtained from screening visit)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2x upper limit of normal (ULN) and total bilirubin (Tbili) 1.5x ULN at randomization (obtained from screening visit)
Serum folate and vitamin B12 > LLN (obtained from screening visit)

Exclusion Criteria

Uncontrolled hypertension as judged by the principal investigator in the 2 weeks prior to screening
Known hematologic disease other than anemia associated with CKD
Known malignancy within the past 5 years before screening
Any prior organ transplant or any planned organ transplant during the study period
Any RBC transfusion during the past 8 weeks before screening
Any condition leading to significant blood loss (e.g., gastrointestinal bleeding, surgical procedures) within 8 weeks before screening or during the screening period
History of chronic liver disease
Pure red cell aplasia (PRCA) or history of PRCA
History of epileptic seizures
History of hyperlipidemia or significant thrombotic/thromboembolic event (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction)
History of thrombosis of an arteriovenous fistula/graft within 12 weeks prior to enrollment
Any active systemic or significant infection or episode of peritonitis within 30 days of screening
Any statin use within 30 days of screening
Any prior exposure to roxadustat or any other HIF-PH inhibitor
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note